Metrics to compare | BETR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBETRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −35.8x | −5.0x | −0.4x | |
PEG Ratio | −3.20 | 0.01 | 0.00 | |
Price/Book | −7.0x | 2.4x | 2.6x | |
Price / LTM Sales | - | 0.8x | 3.1x | |
Upside (Analyst Target) | - | 102.9% | 48.5% | |
Fair Value Upside | Unlock | 3.1% | 5.8% | Unlock |
BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.